Efficacy and safety of extemporaneously prepared miconazole eye drops in Candida albicans-induced keratomycosis
- 56 Downloads
Extemporaneously prepared miconazole eye drops (EPMD) are used by some eye care practitioners to manage keratomycosis in Ghana. This study therefore aimed to determine the efficacy and safety of EPMD using in vitro and in vivo experimental models.
The minimum inhibitory concentration (MIC) of EPMD was determined by the agar-well diffusion method. In vivo, the activity of EPMD on corneal ulcer, neovascularization, clouding, edema, carring and on keratomycotic conjunctivitis and corneal scarring (clinical features) associated with Candida albicans-induced keratomycosis in rabbits was determined by treating them with 0.034–1.08% (weight-in-volume) EPMD for a period of 30 days. The safety of EPMD on the healthy eye was determined by instilling various concentrations into the intact eye of the rabbits.
The MIC of EPMD on Candida albicans was 1.08% (zone of inhibition of 13 mm ± 0.578), which resulted in significantly better improvements (p ≤ 0.001) in clinical findings than eyes treated with sterile water (p > 0.05), and showed no significant difference (p > 0.05) compared to eyes treated with 0.3% fluconazole. There were no visible signs of ocular toxicity on instilling it into healthy eyes of rabbits.
The extemporaneously prepared miconazole eye drops are effective and safe to use in keratomycosis.
KeywordsMinimum inhibitory concentration Corneal neovascularization Oculomycosis Corneal edema Corneal ulcer Fluconazole
This study was funded solely by the authors.
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no conflict of interest whatsoever.
All activities performed during the studies conformed to accepted principles for laboratory animal use and care (EU directive of 1986: 86/609/EEC) and the Association for Research in Vision and Ophthalmology Statement for Use of Animals in Ophthalmic and Vision Research. Institutional guidelines regarding animal experimentation in Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, were followed. Biosafety guidelines for protection of personnel in the laboratory were observed. The project was approved by the animal research review committee of the pharmacology laboratory at the Faculty of Pharmacy and Pharmaceutical Sciences, KNUST (Ethics Reference No: FPPS/PCOL/011/2013).
- 2.Ansari Z, Miller D, Galor A (2013) Current thoughts in fungal keratitis: diagnosis and treatment. Curr Fungal Infect Rep 7(3):209–218. doi: 10.1007/s12281-013-0150-110.1007/s12281-013-0150-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Islam MA, Alam MM, Choudhury ME, Kobayashi N, Ahmed MU (2008) Determination of minimum inhibitory concentration (MIC) of Cloxacillin for selected isolates of Methicillin-resistant staphylococcus aureus (MRSA) with their antibiogram. Bangladesh J Vet Med 6(1):121–126. doi: 10.3329/bjvm.v6i1.1350 CrossRefGoogle Scholar
- 14.Sudan R, Sharma YR (2003) Keratomycosis: clinical diagnosis, medical and surgical treatment. JK Sci 5(1):3–10Google Scholar
- 31.Mun EA, Morrison PWJ, Williams AC, Khutoryanskiy VV (2014) On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein. Mol Pharm 11(10):3556–3564. doi: 10.1021/mp500332m CrossRefPubMedPubMedCentralGoogle Scholar